192332-48-2

Basic information

• Product Name: N'-hydroxy-4-nitrobenzimidamide
• Synonyms: N'-hydroxy-4-nitrobenzimidamide
• CAS NO: 192332-48-2
• Molecular Weight: 181.151
• Mol File: 192332-48-2.mol
• Article Data: 69

Chemical Properties

• CAS DataBase Reference: N'-hydroxy-4-nitrobenzimidamide(CAS DataBase Reference)
• NIST Chemistry Reference: N'-hydroxy-4-nitrobenzimidamide(192332-48-2)
• EPA Substance Registry System: N'-hydroxy-4-nitrobenzimidamide(192332-48-2)

Safety Data

• Hazardous Substances Data: 192332-48-2(Hazardous Substances Data)

Upstream product

• 1011-84-3 4-nitrobenzohydroximoyl chloride 
• 619-72-7 4-nitrobenzonitrile 
• 68451-75-2 C₁₄H₁₁N₃O₄ 
• 124-41-4 sodium methylate 
• 5470-11-1 hydroxylamine hydrochloride 
• 937-31-5 (4-Nitrophenyl)acetylene 
• 172469-59-9 4-(4-Nitro-phenyl)-2λ⁴-[1,2,3,5]oxathiadiazol-2-ylamine 
• 584-08-7 potassium carbonate 
• 555-16-8 4-nitrobenzaldehdye 
• 68451-82-1 C₁₅H₁₃N₃O₅ 
• 68451-95-6 (Z)-4-nitro-N'-((4-nitrobenzoyl)oxy)benzimidamide 
• 68451-89-8 C₁₄H₁₀ClN₃O₄ 
• 586-78-7 para-nitrophenyl bromide 
• 2574-03-0 p-nitrobenzonitrile oxide 

Downstream Products

• 19932-97-9 3-p-nitrophenyl-4,5-dihydro-1,2,4-oxadiazol-5-one 
• 104849-79-8 N-ethoxycarbonyloxy-4-nitro-benzamidine 
• 25283-95-8 3-(4-nitro)phenyl-5-phenyl-[1,2,4]oxadiazole 
• 69792-95-6 5-methyl-3-(4-nitro-phenyl)-2⁽⁴⁾,5-dihydro-[1,2,4]oxadiazole 
• 16013-14-2 3-(4-nitrophenyl)-[1,2,4]oxadiazole 
• 142114-77-0 4-methyl-2-(4-nitrophenyl)pyrimidine 3-oxide 
• 129137-59-3 3-(4-Nitro-phenyl)-5-(2,4,5-trimethyl-phenyl)-[1,2,4]oxadiazole 
• 104849-79-8 C₁₀H₁₁N₃O₅ 
• 77533-95-0 3-p-nitrophenyl-5,5-pentamethylene-Δ²-1,2,4-oxadiazoline 
• 54608-83-2 3,5-bis(p-nitrophenyl)-1,2,4-oxadiazole 
• 111457-49-9 C₉H₈ClN₃O₄ 
• 142114-75-8 4,6-dimethyl-2-(4-nitrophenyl)pyrimidine 1-oxide 
• 142114-71-4 5-methyl-2-(4-nitrophenyl)pyrimidine 1-oxide 
• 110991-37-2 3-p-nitrophenyl-4,5-dihydro-1,2,4-thiadiazol-5-one 

Relevant articles and documents

Novel chalcone/aryl carboximidamide hybrids as potent anti-inflammatory via inhibition of prostaglandin E2 and inducible NO synthase activities: design, synthesis, molecular docking studies and ADMET prediction

Two series of chalcone/aryl carboximidamide hybrids 4a–f and 6a–f were synthesised and evaluated for their inhibitory activity against iNOS and PGE2. The most potent derivatives were further checked for their in?vivo anti-inflammatory activity utilising carrageenan-induced rat paw oedema model. Compounds 4c, 4d, 6c and 6d were proved to be the most effective inhibitors of PGE2, LPS-induced NO production, iNOS activity. Moreover, 4c, 4d, 6c and 6d showed significant oedema inhibition ranging from 62.21% to 78.51%, compared to indomethacin (56.27 ± 2.14%) and celecoxib (12.32%). Additionally, 4c, 6a and 6e displayed good COX2 inhibitory activity while 4c, 6a and 6c exhibited the highest 5LOX inhibitory activity. Compounds 4c, 4d, 6c and 6d fit nicely into the pocket of iNOS protein (PDB ID: 1r35) via the important amino acid residues. Prediction of physicochemical parameters exhibited that 4c, 4d, 6c and 6d had acceptable physicochemical parameters and drug-likeness. The results indicated that chalcone/aryl carboximidamides 4c, 4d, 6c and 6d, in particular 4d and 6d, could be used as promising lead candidates as potent anti-inflammatory agents.

Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study

New antibacterial drugs are urgently needed to tackle the rapid rise in multi-drug resistant bacteria. DNA gyrase is a validated target for the development of new antibacterial drugs. Thus, in the present investigation, a novel series of 1,2,4-oxadiazole-

New 1,2,4-oxadiazole derivatives with positive mGlu4 receptor modulation activity and antipsychotic-like properties

Considering the allosteric regulation of mGlu receptors for potential therapeutic applications, we developed a group of 1,2,4-oxadiazole derivatives that displayed mGlu4 receptor positive allosteric modulatory activity (EC50 = 282–656 nM). Selectivity screening revealed that they were devoid of activity at mGlu1, mGlu2 and mGlu5 receptors, but modulated mGlu7 and mGlu8 receptors, thus were classified as group III-preferring mGlu receptor agents. None of the compounds was active towards hERG channels or in the mini-AMES test. The most potent in?vitro mGlu4 PAM derivative 52 (N-(3-chloro-4-(5-(2-chlorophenyl)-1,2,4-oxadiazol-3-yl)phenyl)picolinamide) was readily absorbed after i.p. administration (male Albino Swiss mice) and reached a maximum brain concentration of 949.76 ng/mL. Five modulators (34, 37, 52, 60 and 62) demonstrated significant anxiolytic- and antipsychotic-like properties in the SIH and DOI-induced head twitch test, respectively. Promising data were obtained, especially for N-(4-(5-(2-chlorophenyl)-1,2,4-oxadiazol-3-yl)-3-methylphenyl)picolinamide (62), whose effects in the DOI-induced head twitch test were comparable to those of clozapine and better than those reported for the selective mGlu4 PAM ADX88178.

2-(1,2,4-Oxadiazol-5-yl)anilines Based on Amidoximes and Isatoic Anhydrides: Synthesis and Structure Features

Abstract: An efficient one-pot method was developed for the synthesis of 2-(1,2,4-oxadiazol-5-yl)anilines via the reaction of amidoximes with isatoic anhydrides in a NaOH–DMSO medium at ambient temperature. The method allows to obtain structurally diverse